A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 30 Jun 2009 Actual end date (January 2008) added as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2005 New trial record.